http://www.biotechdaily.com.au/pages/dr-borehams-crucible.php

Dr Boreham's Crucible

 

 

 

Biotech Daily is delighted to announce that former Criterion writer for The Australian, Tim Boreham, will contribute regular analyses of the sector.

Tim is an experienced business writer having written for three decades at major business publications, specializing in banking, accounting, resources, technology, telecoms, agriculture, property trusts and - of course - the life sciences.

Tim was best known as the writer of the Criterion investment column analyzing ASX-listed companies in a style accessible to retail investors. A quirk of the column was that it offered 'buy' and 'sell' recommendations in a journalist context.

Tim is proud to have no financial qualifications other than an outdated Certificate in Financial Markets and a dedicated following from investors, brokers and analysts and says he is yet to be charged by ASIC despite penning Criterion for more than 10 years.

Tim holds a Bachelor of Arts in Journalism from the Royal Melbourne Institute of Technology.

 

 

 

 

Dr Boreham's Crucible          
 
 
 
 
Adalta (Jun 23, 2017)
 
Genetic Technologies (Jun 16, 2017)
 
Ellex Medical Lasers (Jun 9, 2017)
 
Analytica (Jun 2, 2017)
 
Cochlear (May 26, 2017)
 
Medical Developments (May 19, 2017)
 
GI Dynamics (May 12, 2017)
 
Oncosil (May 5, 2017)
 
Pharmaxis (Apr 28, 2017)
 
Osprey Medical (Apr 21, 2017)
 
LBT Innovations (Apr 13, 2017)
 
Opthea (Apr 7, 2017)
 
Innate (Mar 31, 2017)
 
Bionomics (Mar 24, 2017)
 
Mayne Pharma (Mar 17, 2017)
 
Neuren (Mar 10, 2017) 
 
Volpara (Mar 3, 2017)
 
Mesoblast (Feb 24, 2017)
 
Resapp Health (Feb 17, 2017)
 
Viralytics (Feb 10, 2017)
 
Medical Marijuana (Feb 3, 2017)
 
Sirtex Medical (Jan 23, 2017) 
 
 
 
 
 
 
 
* Disclosure: Dr Boreham is not a qualified medical practitioner and does not possess a doctorate of any sort. Nor is he a licenced financial adviser.

 

Go to Tim's Website